Providers

Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).

Researchers and organizations must collaborate to address the persistent disparities in access to treatments for multiple myeloma, explained Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation.

Clinicians and nurses who treat patients with hemophilia with a gene therapy identified important factors and considerations needed in a potential shared decision making tool.

Joseph Aracri, DO, Allegheny Health Network, spoke with The American Journal of Managed Care® about preventing respiratory syncytial virus (RSV) through immunoglobulin-based treatments and everyday actions.

There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation.

The US Preventive Services Task Force (USPSTF) has recommended that clinicians prescribe pre-exposure prophylaxis (PrEP) to decrease the risk of acquiring HIV.

The respiratory syncytial virus (RSV) vaccine Abrysvo is approved for use in pregnant individuals to prevent RSV in infants up to 6 months of age.

Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment failure compared with other PSA-based definitions.

In this multicenter cohort study, COVID-19 vaccination at any gestational stage improved antibody responses for pregnant individuals and their infants. Booster vaccine recipients demonstrated increased benefits in these effects at delivery.

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe and effective.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

Researchers analyzed numerous biomarkers in patients at risk for inflammatory arthritis to develop measurable scores indicating a patient's vulnerability to disease progression.

New research demonstrated varying trends in early-onset cancer incidence based on race, sex, age, and cancer type.

Greater attention needs to be on educating patients who are switching from a reference product they are successful on to a biosimilar than a patient who is starting a treatment with a biosimilar at the beginning of their disease journey, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.

Data on 10 social determinants of health (SDOH) were analyzed to determine their distribution among low-income patients hospitalized for heart failure (HF) at a safety-net hospital.

The Panicos are on a mission to change how we think about gout. Why? As a husband-and-wife DO duo, the Panicos each have a unique perspective on gout and how physicians in their respective fields can better collaborate to help patients who live with this systemic disease.

The presence of sex differences in immunological functioning influences hidradenitis suppurativa (HS).

New research suggests that measuring the inflammatory marker myeloperoxidase (MPO) may be an effective strategy for the prediction of patients' risk of mortality in a myriad of cardiac—and potentially non-cardiac—diseases.

Findings from a retrospective analysis suggest an association between bridging therapy and poorer outcomes among patients with aggressive, relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

New biomarker technology shows promising results for predicting the prognosis of patients with prostate cancer after radical prostatectomy.

New research found that ovarian cancer risk is reduced by salpingectomy just as much as by tubal ligation, contradicting guidelines that suggest otherwise.

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.